The use of perifosine in a drug combination that appears to work makes a lot of sense, essentially cutting off a cancer's "get around" to a specific pathway block. I don't see this as a weakness in trial design but as a smart move to select patients that are likely to benefit from Perifosine. Drug combinations in Cancer are the wave of future IMO.
they're used to the heat, this is what they do for a living and the SEC would never do anything at all if Justice Dept. didn't have jurisdiction over criminal activity, maybe they crossed the line, let’s hope so and that someone at DOJ notices or has some interest in investigating possible racketeering.
Can someone address the "flaws" pointed out by AF?Namely,the original study of numerous cancers,unplanned looks at interim data,recruiting 13 additional patients,etc...This would appear to compromise the trial?
They found that patients with CRC responded to perifosine, so they disbanded the other indications and recruited more CRC patients and ran a double blind, placebo controlled trial.
It wasn't unplanned, they did it to see what type of cancer was responding. They then spun it into the phase 2 trial.
I do not see how this would compromise the results. He has a valid point that there was a little bit of data dredging when pulling out the indication for refractory CRC as the trial was not designed to study it specifically, but in general, the points are non-sense.
This new piece by AF is exactly why it is hard to stop discussing AF and if he has an impact on AEZS/Keryx share price(s). A 7 page retort to outraged investors because of his original publication shows it must have some effect...IMO. And he still can only summize that big pharma have peeked at data under the non-disclosure act. Screw AF and all his guesses. GLTA Bones